The heavy selling pressure might have exhausted for BioLife Solutions (BLFS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
BioLife Solutions has executed a successful turnaround by refocusing on core biopreservation media and vials, divesting non-core assets. BLFS expects 17–20% revenue growth in FY26, positive GAAP net income, and mid-60s gross margins, supported by dominant CGT market share. Strategic acquisitions like PanTHERA and partnerships such as QKine are set to drive ARPU expansion and next-gen product launches by late 2026.
The mean of analysts' price targets for BioLife Solutions (BLFS) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioLife Solutions, Inc. (NASDAQ: BLFS - Get Free Report)'s stock price gapped up before the market opened on Friday. The stock had previously closed at $22.48, but opened at $23.50. BioLife Solutions shares last traded at $25.01, with a volume of 191,296 shares changing hands. More BioLife Solutions News Here are the key news stories
BioLife Solutions, Inc. (BLFS) Q4 2025 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.01 per share a year ago.
Fourth quarter 2025 revenue from continuing operations of $24.8 million, up 20% year-over-year; Full year 2025 revenue of $96.2 million, up 29% year-over-year GAAP gross margin of 63% and non-GAAP adjusted gross margin of 64% for the fourth quarter GAAP net income of $2.1 million or $0.04 per share and adjusted EBITDA of $6.9 million, or 28% of total revenue for the fourth quarter Expects 2026 revenue growth of $112.5 million to $115.0 million, up 17%-20% over 2025 Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.
BOTHELL, Wash., Feb. 17, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2025 fourth quarter and full year financial results will be released on February 26, 2026.
BOTHELL, Wash., Feb. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain cytokine and growth factor products manufactured by Qkine for use in cell and gene therapy manufacturing.
BioLife Solutions, Inc. (NASDAQ: BLFS - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $25.12 and traded as low as $21.96. BioLife Solutions shares last traded at $22.67, with a volume of 687,757 shares trading hands.
The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
Campbell and CO Investment Adviser LLC raised its stake in shares of BioLife Solutions, Inc. (NASDAQ: BLFS) by 160.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,533 shares of the medical equipment provider's stock after
BioLife Solutions (NASDAQ: BLFS - Get Free Report) and Generation Alpha (OTCMKTS:GNAL - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk. Analyst Ratings This is a summary of recent
Fourth quarter unaudited revenue from continuing operations of $24.8 million increased 20% from the prior year fourth quarter Full year unaudited revenue from continuing operations of $96.2 million exceeded the high end of the previously raised guidance range for FY 2025 BOTHELL, Wash., Jan. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, today announced preliminary fourth quarter and full year 2025 unaudited revenue from continuing operations.
Envista (NYSE: NVST - Get Free Report) and BioLife Solutions (NASDAQ: BLFS - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership. Risk and Volatility Envista has a beta of 0.99,
Terumo (OTCMKTS:TRUMY - Get Free Report) and BioLife Solutions (NASDAQ: BLFS - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation. Analyst Ratings This is a summary of recent ratings
The CFO sold 30,000 shares for $771,600. This transaction represented 16.4% of Wichterman's direct holdings, reducing his direct stake to 152,769 shares.
Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in BioLife Solutions, Inc. (NASDAQ: BLFS) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 9,524 shares of the medical equipment provider's stock, valued at approximately $205,000. Several other hedge
New conference and laboratory facility to showcase the company's product portfolio and serve as a research and training hub to advance biopreservation and cell processing innovation BOTHELL, Wash. , Nov. 20, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced the opening of the Aby J.